Evidence map›Paper›PMID 42182324›Full record

ArticlebioRxiv : the preprint server for biology2026

A

Christopher Bower-Lepts, Arvind Jangra, Sachie Kanatani, Abhai Tripathi, Godfree Mlambo, Alejandro McCotter-González, Linda Romano, Stephen Orena, Martin Okitwi, Karamoko Niaré and 4 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Christopher Bower-LeptsDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Centre, New York, NY, USA.
Arvind JangraDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Centre, New York, NY, USA.
Sachie KanataniDepartment of Molecular Microbiology & Immunology and the Johns Hopkins Malaria Research Institute, Johns Hopkins School of Public Health, Baltimore, MD, USA.
Abhai TripathiDepartment of Molecular Microbiology & Immunology and the Johns Hopkins Malaria Research Institute, Johns Hopkins School of Public Health, Baltimore, MD, USA.
Godfree MlamboDepartment of Molecular Microbiology & Immunology and the Johns Hopkins Malaria Research Institute, Johns Hopkins School of Public Health, Baltimore, MD, USA.
Alejandro McCotter-GonzálezDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Centre, New York, NY, USA.
Linda RomanoDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Centre, New York, NY, USA.
Stephen OrenaInfectious Diseases Research Collaboration, Kampala, Uganda.
Martin OkitwiInfectious Diseases Research Collaboration, Kampala, Uganda.
Karamoko NiaréDepartment of Pathology and Laboratory Medicine, Brown University, Providence, RI, USA.
Philip J RosenthalDepartment of Medicine, University of California, San Francisco, CA, USA.
Melissa ConradDepartment of Molecular Microbiology & Immunology and the Johns Hopkins Malaria Research Institute, Johns Hopkins School of Public Health, Baltimore, MD, USA.
Photini SinnisDepartment of Molecular Microbiology & Immunology and the Johns Hopkins Malaria Research Institute, Johns Hopkins School of Public Health, Baltimore, MD, USA.
Sachel MokDivision of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Centre, New York, NY, USA.

Funding

Resistance of Malaria Parasites to Artemisinin-Based TherapiesR01AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2009 to 2024
$8.4M
Surveillance to track and characterize antimalarial resistance trends in Ugandan Plasmodium falciparum parasites (STARTUP)R01AI173557 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Melissa D Conrad · 2023 to 2026
$2.9M
The genetic basis of emerging multidrug resistance in Plasmodium falciparum African malariaR01AI182318 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Sachel Mok · 2024 to 2026
$1.9M
Resistance of Malaria Parasites to Artemisinin-Based Combination TherapiesR56AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2008 to 2008
$618k
NIAID NIH HHS R01 AI075045NIAID NIH HHS R01 AI173557NIAID NIH HHS R01 AI182318NIAID NIH HHS R56 AI075045
6 · The paper itself

Abstract

Effective control of falciparum malaria depends on the sustained efficacy of frontline antimalarial drugs, particularly artemether-lumefantrine (AL), the most widely used therapy in Africa. However, the emergence of artemisinin partial resistance and reduced lumefantrine susceptibility in eastern Africa threaten malaria control and elimination. Robust genetic markers of decreased susceptibility to lumefantrine remain elusive, and our understanding of artemisinin resistance is incomplete. We report results of a

Identifiers

PMID42182324
PMCPMC13192928

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.